Obesity Medicine 2026 – GLP1R Agonists: What We Know, What We Don t, and What Comes Next (Recorded)

GLP-1 receptor agonists have transformed obesity and diabetes treatment, but their therapeutic effects extend far beyond appetite suppression and glycemic control. This session takes a deeper look at the mechanisms behind GLP-1 efficacy especially their impact on inflammation, neural signaling, and long-term physiology. A central focus will be the modulation of interleukin-6 (IL-6), a cytokine with both pro-inflammatory and homeostatic roles. While GLP-1 agents reduce IL-6 expression and resolve neuroinflammation, chronic suppression may carry trade-offs, including potential impacts on immune resilience, exercise adaptation, and lean body mass. This talk explores pharmacologic vs. physiologic GLP-1 activity, providing context for both the benefits and side effects such as ophthalmic disease, pancreatitis, and sarcopenia. By integrating immunology, neurobiology, and clinical application, attendees will gain a systems-level understanding of GLP-1 therapy and a framework for more personalized, safer, and future-ready prescribing. CME/CE Expiration Date: 4/12/29 *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Pricing

$25

Standard

Listed by the provider · academy.obesitymedicine.org

On-demand / recorded video
Credit · Up to 1 credit
$25

Released

Apr 12, 2026
Last day to claim credit

Apr 13, 2029 3 years left

Individual Course (pay-per-activity)	$21
All Access Pass – OMA Member	$2,000/yr
All Access Pass – Non-Member	$3,000/yr

Obesity Medicine 2026 – GLP1R Agonists: What We Know, What We Don t, and What Comes Next (Recorded)

Related courses

More from Obesity Medicine Association